Edwards Lifesciences announced on April 18, 2025, new eight-year data confirming the long-term durability of its proprietary RESILIA tissue in aortic surgical valves. The study, presented at the Heart Valve Society Annual Meeting, involved 947 patients and marked the first long-term, propensity-matched comparison between RESILIA tissue and non-RESILIA tissue surgical aortic valves.
The data reported encouraging results through eight years, showing significantly improved long-term outcomes for patients receiving RESILIA tissue valves. Specifically, there was 99.3% freedom from structural valve deterioration and 99.2% freedom from reoperation due to SVD in the RESILIA tissue group, compared to 90.5% and 93.9% respectively in the non-RESILIA tissue group.
This significant advancement in tissue technology highlights Edwards’ dedication to pioneering unique innovations and improving patient outcomes. With over 450,000 patients worldwide treated with Edwards’ surgical or TAVR valves with RESILIA tissue, these data further validate its expanding role in structural heart disease treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.